Texas Medical Board Statement Regarding COVID-19 Treatments

Translate to Spanish or other 102 languages!

Image for illustration purposes only

Mega Doctor News

- Advertisement -

The Texas Medical Board is aware of sometimes conflicting information being published regarding COVID-19. In the past week, there was a widely published claim of a “cure” for COVID-19. As we are all aware the medical community is still learning, researching, and gaining an understanding of the virus. While there are drugs and therapies being used to treat COVID-19, there is no definitive cure at this time. 

Both patients and physicians have a right to decide what treatment may be used for COVID-19. The Board does not issue endorsements of the use of any specific drugs or treatments for COVID-19, but any treatment decision must be made with full, proper, and accurate disclosure by a physician.

Physicians should refer to laws and Board rules, including those for complementary and alternative medicine when considering potential treatments and medical decisions regarding COVID-19. A physician must provide full disclosure of treatment options, side effects, obtain informed consent, and there cannot be false, misleading, or deceptive advertising or statements made regarding any therapies, including a cure for COVID-19. 

- Advertisement -

If the Board were to receive a complaint, it would be reviewed following the Board’s standard enforcement process and may include a standard of care review by outside third-party physician experts if the matter involves the treatment of a patient. The Board may also investigate complaints for false, misleading, or deceptive advertising, which could include assuring a permanent cure for an incurable disease.

TMB will continue to provide any updates on COVID-19 issues on the TMB website at www.tmb.state.tx.us/page/coronavirus.

For the latest COVID-19 information for health providers and the public, visit the Department of State Health Services (DSHS) COVID-19 web page at dshs.texas.gov/coronavirus/.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

FDA Approves First Factor Xla Inhibitor to Help Prevent Stroke in Certain Adults at High Risk 

The U.S. Food and Drug Administration today approved Sunharbo (asundexian) 50 mg tablets, the first factor XIa (FXIa) inhibitor for use in combination with antiplatelet therapy to reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke (a stroke caused by a clot that did not originate in the heart) or a high-risk transient ischemic attack (TIA), often called a “mini-stroke.” 

DHR Health Expands Ophthalmology Services with Addition of Dr. Rachel Gelman

 Continuing its mission to provide exceptional medical care to patients across the Rio Grande Valley, DHR Health is pleased to welcome ophthalmologist Dr. Rachel Gelman to its team of healthcare providers.

STHS McAllen Welcomes Aspiring Youth for an Interactive Look Inside Healthcare

As the demand for healthcare professionals continues to grow, introducing young students to the wide range of opportunities available in the medical field is more important than ever. From nurses and physicians to emergency responders, pharmacists and other essential healthcare workers, each plays a critical role in caring for patients and keeping communities healthy.

South Texas Health System Invests $25,000 in VIDA to Expand Healthcare Career Opportunities in the RGV

To help address the ongoing need for qualified workers in the Rio Grande Valley, South Texas Health System (STHS) has renewed its support of Valley Initiative for Development and Advancement (VIDA) through a $25,000 annual grant.
- Advertisement -